Enercap Holdings and Apex Investments in Joint Venture to Build the World’s Largest Supercap Energy Storage Capacity to Meet Exploding Demand
Dubai-based supercap energy storage manufacturer Enercap Holdings and Abu Dhabi-based Apex Investments PSC have formed a joint venture to build 16GWh per year manufacturing capacity of supercap energy storage, a cutting-edge technology with features that surpass the current lithium-ion technology we commonly see. The joint venture is set to meet exponential growth in demand. This will currently be the largest supercap energy storage manufacturing capacity in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240916055477/en/
From left to right - Waseem Ashraf Qureshi, CEO-CTO Enercap, H.E. Khalifah Khoury Chairman Apex Investment and Enercap Energy Holdings, and Mark Blackwell CEO Apex Investments (Photo: AETOSWire)
As part of this collaboration, Enercap Energy Holding Limited, the joint venture, will establish a fully automated 10 GWh/year manufacturing facility in Abu Dhabi. Additionally, Enercap Energy Holding Limited has agreed to acquire an existing manufacturing facility in Dubai Industrial City which will be upgraded to 6 GWh/year capacity. Enercap has a current global demand of over 30GWH of large-scale battery energy storage units (BESS). Apex Energy Holding Limited will take 65% and Enercap SPV Limited 35% of the share capital in the joint-venture.
Enercap’s supercap-based energy storage’s non-degrading, long lasting attribute, along with the ability to operate in wide temperatures, allows it to deliver consistent and predictable capacity over its 25-year life cycle, which is essential for the bankability that the market values when making energy storage investments.
Mark Blackwell, CEO of Apex, said, “Stable, predictable and long-life performance from energy storage is essential to efficiently scale its deployment with renewable generation to replace fossil fuel-based electricity generation. The benefits of supercap storage are driving demand and we are excited to support Waseem Qureshi and his team in their vision to build capacity to enable decarbonization, electrification and the shift to supercap based energy storage.”
Waseem Ashraf Qureshi, CEO of Enercap Holdings and the inventor of the technology, commented, “We are delighted with the joint-venture with Apex which will accelerate our growth throughout the world and expand our product portfolio to deliver solutions in every application where storage is deployed. We believe that this is the future of energy storage.”
Supercap energy storage delivers storage solutions that are long lasting, degradation free, fast charging, safe, fully recyclable and cost effective. “Enercap’s proprietary and disruptive technology will play an important role to accelerate global decarbonization ambition, with its technology serving the energy storage, electric vehicle and consumer markets.” -Mark Blackwell.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916055477/en/
Contacts
Vinod
vt@zenithglobalmedia.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom